Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 14.5% Potential Upside Indicated by Citigroup
broker ratings

Hikma Pharmaceuticals Plc 14.5% Potential Upside Indicated by Citigroup

Hikma Pharmaceuticals Plc with EPIC/TICKER (LON:HIK) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Citigroup. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Citigroup have set a target price of 2100 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 14.5% from the opening price of 1833.5 GBX. Over the last 30 and 90 trading days the company share price has increased 228.5 points and increased 438 points respectively. The 1 year high for the stock price is 1867.5 GBX while the 52 week low for the stock is 814.2 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,564.39 GBX and a 200 Day Moving Average share price is recorded at 1,239.41. There are currently 241,421,136 shares in issue with the average daily volume traded being 1,008,334. Market capitalisation for LON:HIK is £4,391,333,872 GBP.